This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kurebayashi, J. Articles by Sonoo, H. Search for Related Content PubMed PubMed Citation Articles by Kurebayashi, J. Articles by Sonoo, H.

All-Trans-Retinoic Acid Modulates Expression Levels of Thyroglobulin and Cytokines in a New Human Poorly Differentiated Papillary Thyroid Carcinoma Cell Line, KTC-1¹

Departments of Breast and Thyroid Surgery (J.K., K.T., H.K., H.S.), Hygiene (T.O.), and Radiation Oncology (M.U.), Kawasaki Medical School, Kurashiki, Okayama 701-0192; and Department of Pathology, Tohoku University School of Medicine (T.M.), Sendai, Miyagi 980-8574, Japan

Address all correspondence and requests for reprints to: Junichi Kurebayashi, M.D., Department of Breast and Thyroid Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701-0192, Japan. E-mail: kure{at}med.kawasaki-m.ac.jp

A new human thyroid carcinoma cell line, KTC-1, was established from the malignant pleural effusion of a recurrent thyroid carcinoma patient. Cytogenetic analysis revealed a normal karyotype, and no p53 mutation in exons 5–9 was detected. This cell line is tumorigenic in athymic nude mice. Histological findings by light and electron microscopy, such as the absence of follicular structures and the existence of intranuclear cytoplasmic inclusions and psammoma bodies, indicated transplanted tumors to be a poorly differentiated papillary thyroid carcinoma. A low expression level of thyroglobulin was detected by immunocytochemistry and RT-PCR. Messenger ribonucleic acid (mRNA) expression of thyroid transcription factor-1 and PAX-8 was also detected. No mRNA expression of TSH receptors, thyroid peroxidase, or Na⁺/I^- symporter was detected. Interleukin-6 and leukemia inhibitory factor were secreted into the medium. These findings suggest this cell line to be functionally poorly differentiated. Moreover, all-trans-retinoic acid increased the mRNA expression of thyroglobulin and decreased both the mRNA expression and secretion of interleukin-6 and leukemia inhibitory factor while significantly stimulating growth. RT-PCR analysis of retinoic acid receptors (RARs) revealed that KTC-1 cells express a moderate level of RAR and -, but a low level of RARß. This cell line may be useful for studying redifferentiation therapy for thyroid carcinoma.

This article has been cited by other articles:

				C. J. O'Neill, J. Oucharek, D. Learoyd, and S. B. Sidhu Standard and Emerging Therapies for Metastatic Differentiated Thyroid Cancer Oncologist, February 1, 2010; 15(2): 146 - 156. [Abstract] [Full Text] [PDF]

				R. E. Schweppe, J. P. Klopper, C. Korch, U. Pugazhenthi, M. Benezra, J. A. Knauf, J. A. Fagin, L. A. Marlow, J. A. Copland, R. C. Smallridge, et al. Deoxyribonucleic Acid Profiling Analysis of 40 Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and Misidentification J. Clin. Endocrinol. Metab., November 1, 2008; 93(11): 4331 - 4341. [Abstract] [Full Text] [PDF]

				T. Kondo, X. Zhu, S. L. Asa, and S. Ezzat The Cancer/Testis Antigen Melanoma-Associated Antigen-A3/A6 Is a Novel Target of Fibroblast Growth Factor Receptor 2-IIIb through Histone H3 Modifications in Thyroid Cancer Clin. Cancer Res., August 15, 2007; 13(16): 4713 - 4720. [Abstract] [Full Text] [PDF]

				H.-Q. Wang, Z.-X. Du, H.-Y. Zhang, and D.-X. Gao Different Induction of GRP78 and CHOP as a Predictor of Sensitivity to Proteasome Inhibitors in Thyroid Cancer Cells Endocrinology, July 1, 2007; 148(7): 3258 - 3270. [Abstract] [Full Text] [PDF]

				T. Kondo, L. Zheng, W. Liu, J. Kurebayashi, S. L. Asa, and S. Ezzat Epigenetically Controlled Fibroblast Growth Factor Receptor 2 Signaling Imposes on the RAS/BRAF/Mitogen-Activated Protein Kinase Pathway to Modulate Thyroid Cancer Progression Cancer Res., June 1, 2007; 67(11): 5461 - 5470. [Abstract] [Full Text] [PDF]

				A. Aiello, G. Pandini, F. Frasca, E. Conte, A. Murabito, A. Sacco, M. Genua, R. Vigneri, and A. Belfiore Peroxisomal Proliferator-Activated Receptor-{gamma} Agonists Induce Partial Reversion of Epithelial-Mesenchymal Transition in Anaplastic Thyroid Cancer Cells Endocrinology, September 1, 2006; 147(9): 4463 - 4475. [Abstract] [Full Text] [PDF]

				E. Frohlich, F. Machicao, and R. Wahl Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture Endocr. Relat. Cancer, June 1, 2005; 12(2): 291 - 303. [Abstract] [Full Text] [PDF]

				R. Elisei, A. Vivaldi, L. Agate, R. Ciampi, E. Molinaro, P. Piampiani, C. Romei, P. Faviana, F. Basolo, P. Miccoli, et al. All-Trans-Retinoic Acid Treatment Inhibits the Growth of Retinoic Acid Receptor {beta} Messenger Ribonucleic Acid Expressing Thyroid Cancer Cell Lines but Does Not Reinduce the Expression of Thyroid-Specific Genes J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2403 - 2411. [Abstract] [Full Text] [PDF]

				Y. Takiyama, N. Miyokawa, A. Sugawara, S. Kato, K. Ito, K. Sato, K. Oikawa, H. Kobayashi, S. Kimura, and M. Tateno Decreased Expression of Retinoid X Receptor Isoforms in Human Thyroid Carcinomas J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5851 - 5861. [Abstract] [Full Text] [PDF]

				D. V. Starenki, H. Namba, V. A. Saenko, A. Ohtsuru, S. Maeda, K. Umezawa, and S. Yamashita Induction of Thyroid Cancer Cell Apoptosis by a Novel Nuclear Factor {kappa}B Inhibitor, Dehydroxymethylepoxyquinomicin Clin. Cancer Res., October 15, 2004; 10(20): 6821 - 6829. [Abstract] [Full Text] [PDF]

				B. R. Haugen, L. L. Larson, U. Pugazhenthi, W. R. Hays, J. P. Klopper, C. A. Kramer, and V. Sharma Retinoic Acid and Retinoid X Receptors Are Differentially Expressed in Thyroid Cancer and Thyroid Carcinoma Cell Lines and Predict Response to Treatment with Retinoids J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 272 - 280. [Abstract] [Full Text] [PDF]

				H. Namba, M. Nakashima, T. Hayashi, N. Hayashida, S. Maeda, T. I. Rogounovitch, A. Ohtsuru, V. A. Saenko, T. Kanematsu, and S. Yamashita Clinical Implication of Hot Spot BRAF Mutation, V599E, in Papillary Thyroid Cancers J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4393 - 4397. [Abstract] [Full Text] [PDF]

				A. Podtcheko, A. Ohtsuru, S. Tsuda, H. Namba, V. Saenko, M. Nakashima, N. Mitsutake, S. Kanda, J. Kurebayashi, and S. Yamashita The Selective Tyrosine Kinase Inhibitor, STI571, Inhibits Growth of Anaplastic Thyroid Cancer Cells J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1889 - 1896. [Abstract] [Full Text] [PDF]

				L. Barzon, R. Bonaguro, I. Castagliuolo, M. Chilosi, E. Gnatta, C. Parolin, M. Boscaro, and G. Palu Transcriptionally Targeted Retroviral Vector for Combined Suicide and Immunomodulating Gene Therapy of Thyroid Cancer J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 5304 - 5311. [Abstract] [Full Text] [PDF]

				G. Gorgun and F. Foss Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox Blood, July 30, 2002; 100(4): 1399 - 1403. [Abstract] [Full Text] [PDF]

				J.-D. Lin The role of apoptosis in autoimmune thyroid disorders and thyroid cancer BMJ, June 23, 2001; 322(7301): 1525 - 1527. [Full Text] [PDF]